Abstract
Inflammatory bowel disease (IBD) is a chronic condition that affects the digestive
tract and can lead to inflammation and damage to the intestinal lining. IBD patients
with cancer encounter difficulties since cancer treatment weakens their immune systems.
A multidisciplinary strategy that strikes a balance between the requirement to manage
IBD symptoms and the potential effects of treatment on cancer is necessary for effective
care of IBD in cancer patients. To reduce inflammation and avoid problems, IBD in
cancer patients is often managed by closely monitoring IBD symptoms in conjunction
with the necessary medication and surgical intervention. Anti-inflammatory medications,
immunomodulators, and biologic therapies may be used for medical care, and surgical
options may include resection of the diseased intestine or removal of the entire colon.
The current study provides a paradigm for shared decision-making involving the patient,
gastroenterologist, and oncologist while considering recent findings on the safety
of IBD medicines, cancer, and recurrent cancer risk in individuals with IBD. We hope
to summarize the pertinent research in this review and offer useful advice.
Keywords
Inflammatory bowel disorder - Cancer - treatment - malignancy - Anti-TNF - therapy
- risks - inflammation - immunosuppression
